Korea BNC "Exclusion of 'Stage 5 Patients' in Expanded Clinical Trial Subjects for Antroquinonol"

[Asia Economy Reporter Hyungsoo Park] It has been revealed that the scope of clinical trial subjects for 'Antroquinonol,' currently undergoing clinical trials by Taiwan's Golden Biotech, is narrower than initially disclosed.

On the 3rd, Korea BNC stated in a press release, "Golden Biotech's clinical trial, approved for changes by the FDA, includes hospitalized patients with mild to moderate COVID-19 infection who require oxygen therapy using masks or nasal cannulas (WHO COVID-19 clinical progression scale level 4) in the subject selection criteria."

Previously, on the 30th of last month, Korea BNC had announced that they had received consent to expand subject recruitment from currently enrolled mild to moderate COVID-19 hospitalized patients to severe patients requiring non-invasive ventilation or high-flow oxygen.

The company explained, "This information was published based on Golden Biotech's disclosures and notifications received by our company." They added, "Yesterday, Taiwan's Golden Biotech informed us that the FDA-approved changes to the clinical trial subject selection criteria do not include severe patients (WHO COVID-19 clinical progression scale level 5) who require non-invasive ventilation and high-flow oxygen."

This means the scope is narrower than the previously stated consent to expand subject recruitment from mild or moderate COVID-19 hospitalized patients to severe patients requiring non-invasive ventilation or high-flow oxygen.

Korea BNC introduced that this information can be verified through the clinical trial information site ClinicalTrials.gov. They added that this correction article is published to minimize investor misjudgment.

This content was produced with the assistance of AI translation services.